Zobrazeno 1 - 10
of 533
pro vyhledávání: ''
Publikováno v:
Cancer Medicine, Vol 11, Iss 3, Pp 641-653 (2022)
Background We have limited information about neuroendocrine carcinoma (NEC) of the gallbladder. The purpose of this paper is to compare clinical and pathological features between different age groups and prognostic factors for gallbladder NEC and how
Autor:
Ke Wang, Lin Lei, Ji Peng, Jinrong Xiao, Guanzhong Lu, Sheng Wei, Jiao Huang, Yangkai Li, Ying Liu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 281-294 (2022)
Cancer Medicine, Vol 11, Iss 1, Pp 281-294 (2022)
Background Lung cancer is the leading cause of cancer morbidity and mortality worldwide, however, the individualized treatment is still unsatisfactory. DNA methylation can affect gene regulation and may be one of the most valuable biomarkers in predi
Autor:
Li Pang, Zhiqiang Guo
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8558-8569 (2021)
Cancer Medicine
Cancer Medicine
Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples
Autor:
Jinyi Wang, Guohan Chen, Guangxue Wang, Xuan Hong, Zhiyuan Huang, Tian Zhao, Yejun Cao, Qiying Zhang, Zhengjun Chai, Jie Liu, Qinchuan Li, Yang Han, Zhengliang Sun
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Objective The aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), a
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 176-182 (2022)
Cancer Medicine
Cancer Medicine
Background Xanthogranulomatous cholecystitis (XGC) is an extremely rare entity. Due to XGC’s clinical and radiological resemblance to gallbladder carcinoma (GBC), intraoperative frozen section during cholecystectomy is often performed to exclude th
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Background Many real‐world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population‐based pre
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7572-7584 (2021)
Cancer Medicine
Cancer Medicine
Background Doxorubicin (Dox) is one of the most effective chemotherapy agents used to treat adolescent and young adult sarcoma patients. Unfortunately, Dox causes cardiotoxicities that compromise long‐term survival. We investigated whether exercise
Autor:
Tetsuya Fukumoto, Naoya Sugihara, Kenichi Nishimura, Noriyoshi Miura, Yuki Miyauchi, Ryuta Watanabe, Yuichiro Sawada, Takashi Saika, Keisuke Funaki, Tadahiko Kikugawa, Kanae Koyama, Toshio Kakuda, Terutaka Noda
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 7968-7976 (2021)
Cancer Medicine
Cancer Medicine
Background Patients with very‐high‐risk prostate cancer (VHRPCa) have earlier biochemical recurrences (BCRs) and higher mortality rates. It remains unknown whether extended robot‐assisted laparoscopic prostatectomy (eRALP) without neoadjuvant o
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7610-7619 (2021)
Cancer Medicine
Cancer Medicine
Purpose The study was designed to elucidate the predictive value of the number of lymph node metastases (LNMs) and lymph node ratio (LNR) for response to therapy restratification system (RTRS). Methods From December 2015 to December 2019, 1228 patien
Autor:
Eiji Shinozaki, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Izuma Nakayama, Daisaku Kamiimabeppu, Takeru Wakatsuki, Keitaro Shimozaki, Daisuke Takahari, Akira Ooki
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In contrast, carcinoembryonic antigen (CEA) is a conventional tumor marker for predicting recur